X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (10) 10
index medicus (10) 10
female (9) 9
male (8) 8
adult (7) 7
double-blind method (6) 6
hiv infections - drug therapy (6) 6
middle aged (6) 6
abridged index medicus (5) 5
aged (5) 5
drug therapy (5) 5
infectious diseases (5) 5
anti-hiv agents - administration & dosage (4) 4
clinical trials (4) 4
co-formulated elvitegravir (4) 4
drug combinations (4) 4
health aspects (4) 4
internal medicine (4) 4
medicine, general & internal (4) 4
quinolones - administration & dosage (4) 4
research (4) 4
adenine - administration & dosage (3) 3
adenine - analogs & derivatives (3) 3
aids/hiv (3) 3
antiviral agents (3) 3
carbamates - administration & dosage (3) 3
cobicistat (3) 3
comparative analysis (3) 3
deoxycytidine - administration & dosage (3) 3
deoxycytidine - analogs & derivatives (3) 3
disoproxil fumarate (3) 3
dosage and administration (3) 3
double-blind (3) 3
efavirenz (3) 3
hiv infection (3) 3
hiv infections - virology (3) 3
idiopathic pulmonary fibrosis - mortality (3) 3
immunology (3) 3
initial treatment (3) 3
kaplan-meier estimate (3) 3
mortality (3) 3
non-inferiority trial (3) 3
organophosphonates - administration & dosage (3) 3
protease inhibitors (3) 3
raltegravir (3) 3
single-tablet regimen (3) 3
tenofovir (3) 3
thiazoles - administration & dosage (3) 3
time factors (3) 3
treatment outcome (3) 3
treatment-naive (3) 3
vital capacity (3) 3
young adult (3) 3
adolescent (2) 2
adults (2) 2
aged, 80 and over (2) 2
anti-hiv agents (2) 2
anti-hiv agents - adverse effects (2) 2
antiretroviral drugs (2) 2
care and treatment (2) 2
creatinine (2) 2
data processing (2) 2
design (2) 2
diagnosis (2) 2
emtricitabine (2) 2
hepatitis (2) 2
hiv (2) 2
hiv-1 (2) 2
hiv-1 infection analysis (2) 2
human immunodeficiency virus--hiv (2) 2
idiopathic pulmonary fibrosis - drug therapy (2) 2
infections (2) 2
inhibitors (2) 2
integrase (2) 2
laboratories (2) 2
lung cancer (2) 2
lung diseases (2) 2
lungs (2) 2
patient outcomes (2) 2
patients (2) 2
pharmaceutical industry (2) 2
pharmacology & pharmacy (2) 2
phase-3 (2) 2
proportional hazards models (2) 2
pulmonary diffusing capacity (2) 2
pulmonary fibrosis (2) 2
quinolones - adverse effects (2) 2
quinolones - therapeutic use (2) 2
ribonucleic acid--rna (2) 2
ritonavir (2) 2
ritonavir - administration & dosage (2) 2
rna, viral - blood (2) 2
safety (2) 2
survival (2) 2
tablets - administration & dosage (2) 2
tenofovir disoproxil fumarate (2) 2
usage (2) 2
[sdv.mhep.psr]life sciences [q-bio]/human health and pathology/pulmonology and respiratory tract (1) 1
action project (1) 1
active antiretroviral therapy (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2011, Volume 377, Issue 9779, pp. 1760 - 1769
Journal Article
Lancet, The, ISSN 0140-6736, 2012, Volume 379, Issue 9835, pp. 2429 - 2438
Summary Background The HIV integrase strand transfer inhibitor elvitegravir (EVG) has been co-formulated with the CYP3A4 inhibitor cobicistat (COBI),... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | TREATMENT-NAIVE | PHARMACOKINETICS | RALTEGRAVIR | SAFETY | EFAVIRENZ | ADULTS | SINGLE-TABLET REGIMEN | PATIENTS 96-WEEK EFFICACY | COMBINATION | ADHERENCE | HIV-1 | Humans | Middle Aged | Male | Thiazoles - administration & dosage | Carbamates - administration & dosage | Anti-HIV Agents - administration & dosage | Tenofovir | Atazanavir Sulfate | Adult | Female | Emtricitabine | Adenine - analogs & derivatives | Pyridines - administration & dosage | Double-Blind Method | Ritonavir - administration & dosage | Deoxycytidine - administration & dosage | Adenine - administration & dosage | Organophosphonates - administration & dosage | Quinolones - administration & dosage | HIV Infections - drug therapy | Oligopeptides - administration & dosage | Cobicistat | Deoxycytidine - analogs & derivatives | Drug Combinations | Antiviral agents | Patient outcomes | Dosage and administration | Research | Comparative analysis | Drug therapy | HIV infection | Anti-HIV agents | Antiretroviral drugs | Bone density | Pharmaceutical industry | Human immunodeficiency virus--HIV | Pneumonia | Laboratories | Ritonavir | Liver | Infections | Drug resistance | Hepatitis | Randomization | All terrain vehicles | Creatinine | Integrase | Data processing | Proteinase inhibitors | Behavior disorders | Ribonucleic acid--RNA | Patients | Cholesterol | Glomerular filtration rate | Inhibitors | Protease inhibitors | Interactive systems
Journal Article
Lancet, The, ISSN 0140-6736, 2012, Volume 379, Issue 9835, pp. 2439 - 2448
Journal Article
Journal Article
Lancet HIV, The, ISSN 2352-3018, 2016, Volume 3, Issue 9, pp. e410 - e420
Summary Background Women are under-represented in HIV antiretroviral therapy (ART) studies. Guidelines for selection of ART as initial therapy in patients with... 
Infectious Disease | UNITED-STATES | INFECTIOUS DISEASES | TENOFOVIR DISOPROXIL FUMARATE | TREATMENT-NAIVE | ACTIVE ANTIRETROVIRAL THERAPY | CLINICAL-TRIALS | INITIAL TREATMENT | GENDER | SEX-DIFFERENCES | IMMUNOLOGY | HIV-1 INFECTION | ADVERSE EVENTS | Atazanavir Sulfate - administration & dosage | Humans | RNA, Viral - blood | Tenofovir - administration & dosage | HIV Integrase Inhibitors - administration & dosage | Atazanavir Sulfate - adverse effects | Viral Load | Quinolones - adverse effects | Ritonavir - adverse effects | Quinolones - therapeutic use | Ritonavir - therapeutic use | Adult | Female | Emtricitabine - administration & dosage | HIV Protease Inhibitors - adverse effects | Emtricitabine - adverse effects | Emtricitabine - therapeutic use | Tenofovir - adverse effects | Double-Blind Method | Ritonavir - administration & dosage | Tenofovir - therapeutic use | HIV Infections - virology | Cobicistat - administration & dosage | International Cooperation | HIV Protease Inhibitors - administration & dosage | HIV Protease Inhibitors - therapeutic use | Antiretroviral Therapy, Highly Active | Atazanavir Sulfate - therapeutic use | Quinolones - administration & dosage | HIV Integrase Inhibitors - adverse effects | HIV Integrase Inhibitors - therapeutic use | Cobicistat - adverse effects | HIV Infections - drug therapy | Cobicistat - therapeutic use
Journal Article
JAIDS Journal of Acquired Immune Deficiency Syndromes, ISSN 1525-4135, 05/2013, Volume 63, Issue 1, pp. 96 - 100
We report week 96 results from a phase 3 trial of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (EVG/COBI/FTC/TDF, n = 348) vs... 
HIV | cobicistat | phase 3 randomized trial | safety | efficacy | stribild | INFECTIOUS DISEASES | CO-FORMULATED ELVITEGRAVIR | NON-INFERIORITY TRIAL | PHASE-3 | IMMUNOLOGY | TREATMENT-NAIVE | EFAVIRENZ | LOPINAVIR/RITONAVIR | TENOFOVIR | RITONAVIR | Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination | Humans | Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination | Male | RNA, Viral - blood | Thiazoles - administration & dosage | Carbamates - administration & dosage | Thiazoles - therapeutic use | Thiazoles - adverse effects | Young Adult | Deoxycytidine - therapeutic use | Adenine - adverse effects | HIV-1 - physiology | Quinolones - adverse effects | Adenine - therapeutic use | Quinolones - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Deoxycytidine - adverse effects | Female | Adenine - analogs & derivatives | Double-Blind Method | Organophosphonates - therapeutic use | HIV-1 - drug effects | Anti-HIV Agents - adverse effects | Deoxycytidine - administration & dosage | HIV Infections - virology | Organophosphonates - adverse effects | Treatment Outcome | Adenine - administration & dosage | Oxazines - adverse effects | Organophosphonates - administration & dosage | Quinolones - administration & dosage | Oxazines - therapeutic use | Creatinine - blood | Carbamates - adverse effects | HIV Infections - drug therapy | Carbamates - therapeutic use | Deoxycytidine - analogs & derivatives | Drug Combinations
Journal Article
Journal Article
11/2002, Volume 57, Issue 11
  Survival of patients with lung cancer is approximately 12%, largely because the disease is not detected until it has reached an advanced stage. Past... 
Smoking cessation | Patient education | Lung cancer | Medical screening | Drug therapy
Magazine Article
Magazine Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.